Immunogen (IMGN) 12.49 $IMGN
ImmunoGen Named One of The Boston Globe's Top Places to Work for Third Consecutive Year
Business Wire - Fri Nov 13, 7:00AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work. The Company has received this recognition for the third consecutive year and in four of the last five years.
IMGN: 12.49 (-0.32)
ImmunoGen Refines Drug Targeting for Ovarian Cancer Patients
at The Street - Sun Nov 08, 11:32AM CST
Ovarian cancer patients with tumors expressing high levels of a specific protein on their surface respond best to treatment with ImmunoGen's "smart bomb" cancer drug.
IMGN: 12.49 (-0.32)
Treatment Response to ImmunoGen's Mirvetuximab Soravtansine Found to be Substantially Greater in Ovarian Cancer with High Expression of Folate Receptor Alpha
Business Wire - Sun Nov 08, 11:30AM CST
--Most patients with ovarian cancer found to have high or medium expression of target
IMGN: 12.49 (-0.32)
Global Market Study on Next-Generation Antibody Therapeutics 2015: Biosimilar Antibody Products to Witness Highest Growth by 2022
M2 - Thu Nov 05, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/zq8pjv/global_market) has announced the addition of the "Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022" report to their offering. The global next-generation antibody therapeutics market is projected to be valued at US$ 2,250.0 Mn by the end of 2015. It is likely to grow at a CAGR of 13.0% to account for US$ 6,761.1 Mn by 2022. Success of monoclonal antibodies has encouraged researchers to discover and develop next-generation of antibodies. Next-generation antibody therapeutics are improved antibody therapeutics that are highly efficient, offer greater safety, and are easier to deliver. Globally, the next-generation antibody therapeutics market is witnessing significant growth due to growing R&D activities, increasing prevalence of chronic diseases, and technological advancements in antibody therapeutics. In addition, increasing healthcare expenditure is also driving growth of the global next-generation antibody therapeutics market. However, factors such as high costs of next generation antibody therapeutics, stringent regulatory requirements, and long approval time are restraining growth of the market. North America is the largest market for next-generation antibody therapeutics. In terms of technology, antibody-drug conjugates are the largest segment in the global next-generation antibody therapeutics market. On the basis of therapeutic application, oncology dominates the next-generation antibody therapeutics market. The North America next-generation antibody therapeutics market is anticipated to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. One of the latest trends in the next-generation antibody therapeutics market is the increasing use of ADC technology. Various biotechnology and biopharmaceutical companies are actively involved in development and manufacture of next-generation antibodies. Some of the major players in the market are F. Hoffmann-La Roche Ltd., Dyax Corp., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen, Inc., Biogen, Bayer AG, and Xencor, Inc. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Major Next-generation Antibody Therapeutics Pipeline Drugs Chapter 6 Global Market Size and Forecast Chapter 7 Market Size and Forecast by Therapeutic Area Chapter 8 Market Size and Forecast by Technology Chapter 9 Market Size and Forecast by Geography Chapter 10 Competitive Scenario Chapter 11 Company Profiles - Amgen, Inc. - AstraZeneca - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen, Inc. - Kyowa Hakko Kirin Co., Ltd. - Pfizer, Inc. - Seattle Genetics, Inc. - Takeda Pharmaceuticals Company Limited - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/zq...bal_market
SGEN: 42.81 (+0.46), PFE: 33.27 (-0.12), IMGN: 12.49 (-0.32), AMGN: 151.55 (+0.57), BMY: 64.15 (+0.43), XNCR: 12.97 (+0.09), DYAX: 34.42 (+0.03)
Immunogen Has Returned 11.6% Since SmarTrend Recommendation (IMGN)
Comtex SmarTrend(R) - Wed Nov 04, 12:20PM CST
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 11.59% as of today's recent price of $12.63.
IMGN: 12.49 (-0.32)
ImmunoGen, Inc. Pushes Its Pipeline Forward
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 31, 7:00AM CDT
ImmunoGen reported results from its first fiscal quarter on Tuesday, but there wasn't much to talk about on the financial side. Sales of Kadcyla, the first drug the biotech helped develop, aren't particularly material after ImmunoGen sold the...
JNJ: 99.88 (-0.39), IMGN: 12.49 (-0.32)
Downtrend Call Working As Immunogen Stock Falls 22.2% (IMGN)
Comtex SmarTrend(R) - Wed Oct 28, 10:50AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 22.19% as of today's recent price of $11.12.
IMGN: 12.49 (-0.32)
Shares of IMGN Down 25.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 28, 10:25AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 25.03% as of today's recent price of $10.71.
IMGN: 12.49 (-0.32)
ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 8:40AM CDT
ImmunoGen (IMGN) reported a loss of 39 cents per share in the first quarter fiscal 2016 with total revenues of $14.9 million.
AZN: 31.29 (+0.44), IMGN: 12.49 (-0.32), AMAG: 29.47 (+0.56)
ImmunoGen's (IMGN) Q1FY16 Loss Wider-than-Expected
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 7:34AM CDT
ImmunoGen reported a wider-than-expected loss in the first quarter of fiscal 2016.
IMGN: 12.49 (-0.32)
ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Business Wire - Tue Oct 27, 5:30AM CDT
--Level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine, ImmunoGen's novel folate receptor a (FRa)-targeting antibody-drug conjugate (ADC); data to be reported at AACR-NCI-EORTC in November.
IMGN: 12.49 (-0.32)
What Awaits ImmunoGen (IMGN) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Oct 26, 3:01PM CDT
ImmunoGen (IMGN) to report first quarter fiscal 2016 earnings results on Oct 27 before the market opens.
AQXP: 12.85 (+0.14), IMGN: 12.49 (-0.32), BMY: 64.15 (+0.43)
BUYINS.NET: IMGN SqueezeTrigger Price is $11.24. There is $120,266,048 That Short Sellers Still Need To Cover.
M2 - Mon Oct 26, 11:35AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Immunogen Inc (NASDAQ:IMGN) in real time and just received an alert that IMGN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 10586800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $11.24. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
IMGN: 12.49 (-0.32)
Immunogen Down 25.1% Since SmarTrend Downtrend Call (IMGN)
Comtex SmarTrend(R) - Wed Oct 21, 9:18AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 25.10% as of today's recent price of $10.70.
IMGN: 12.49 (-0.32)
Ergomed Ups the Ante for CEL-SCI
ACCESSWIRE - Wed Oct 21, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Cancer immunotherapy company CEL-SCI Corp. (NYSE MKT: CVM) is thriving. Ergomed, a multinational Contract Research Organization (CRO) with a pristine reputation and the confidence in CEL-SCI's lead drug Multikine to make a huge upfront $10 million investment, recently raised the ante 20% - to $12 million. The deal was done under the same terms first put in place that calls for only a single-digit royalty on potential sales. This clearly shows Ergomed's confidence not only in the likelihood of Multikine being approved, but also in the large revenue potential of the cancer immunotherapy drug.
MNK: 56.94 (+3.53), INO: 7.08 (+0.03), SNTA: 0.43 (-0.01), PCYC: 261.25 (+1.70), ADRO: 29.09 (+0.63), CVM: 0.49 (-0.01), IMGN: 12.49 (-0.32), CLLS: 35.83 (-0.53), AEZS: 0.05 (unch), JUNO: 50.00 (+0.11), BMY: 64.15 (+0.43)
Immunogen Shares Down 28.0% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Tue Oct 13, 4:54PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 28.04% as of today's recent price of $10.28.
IMGN: 12.49 (-0.32)
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results
Business Wire - Tue Oct 13, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Tuesday, October 27, 2015, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2015. Management also will provide an update on the Company.
IMGN: 12.49 (-0.32)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.64 (-0.09), BIIB: 284.84 (-6.49), NWBO: 4.54 (+0.02), CVM: 0.49 (-0.01), CLDX: 14.23 (+0.22), MACK: 9.12 (+0.29), INO: 7.08 (+0.03), NLNK: 35.90 (+0.94), JUNO: 50.00 (+0.11), GALE: 1.50 (+0.02), IMMU: 3.13 (+0.02), ADXS: 13.36 (+0.47), ADRO: 29.09 (+0.63), IMGN: 12.49 (-0.32), AMGN: 151.55 (+0.57), SPPI: 5.24 (+0.17), LLY: 79.55 (-0.31), BMY: 64.15 (+0.43), GSK: 39.87 (-0.18), SRNE: 8.79 (+0.21), ONTY: 3.46 (+0.19), IMUC: 0.46 (-0.01), PGNX: 6.71 (-0.03), ARGS: 4.27 (-0.04), GBIM: 2.21 (-0.22), BLCM: 20.88 (+0.02), SGEN: 42.81 (+0.46), KITE: 81.33 (+1.52), MRK: 53.03 (unch)
Immunogen Has Returned 24.8% Since SmarTrend Recommendation (IMGN)
Comtex SmarTrend(R) - Tue Oct 06, 11:29AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 24.82% as of today's recent price of $10.74.
IMGN: 12.49 (-0.32)
Shares of IMGN Down 30.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 29, 9:53AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 30.07% as of today's recent price of $9.99.
IMGN: 12.49 (-0.32)
ImmunoGen Named One of The Boston Globe's Top Places to Work for Third Consecutive Year
Business Wire - Fri Nov 13, 7:00AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work. The Company has received this recognition for the third consecutive year and in four of the last five years.
IMGN: 12.49 (-0.32)
ImmunoGen Refines Drug Targeting for Ovarian Cancer Patients
at The Street - Sun Nov 08, 11:32AM CST
Ovarian cancer patients with tumors expressing high levels of a specific protein on their surface respond best to treatment with ImmunoGen's "smart bomb" cancer drug.
IMGN: 12.49 (-0.32)
Treatment Response to ImmunoGen's Mirvetuximab Soravtansine Found to be Substantially Greater in Ovarian Cancer with High Expression of Folate Receptor Alpha
Business Wire - Sun Nov 08, 11:30AM CST
--Most patients with ovarian cancer found to have high or medium expression of target
IMGN: 12.49 (-0.32)
Global Market Study on Next-Generation Antibody Therapeutics 2015: Biosimilar Antibody Products to Witness Highest Growth by 2022
M2 - Thu Nov 05, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/zq8pjv/global_market) has announced the addition of the "Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022" report to their offering. The global next-generation antibody therapeutics market is projected to be valued at US$ 2,250.0 Mn by the end of 2015. It is likely to grow at a CAGR of 13.0% to account for US$ 6,761.1 Mn by 2022. Success of monoclonal antibodies has encouraged researchers to discover and develop next-generation of antibodies. Next-generation antibody therapeutics are improved antibody therapeutics that are highly efficient, offer greater safety, and are easier to deliver. Globally, the next-generation antibody therapeutics market is witnessing significant growth due to growing R&D activities, increasing prevalence of chronic diseases, and technological advancements in antibody therapeutics. In addition, increasing healthcare expenditure is also driving growth of the global next-generation antibody therapeutics market. However, factors such as high costs of next generation antibody therapeutics, stringent regulatory requirements, and long approval time are restraining growth of the market. North America is the largest market for next-generation antibody therapeutics. In terms of technology, antibody-drug conjugates are the largest segment in the global next-generation antibody therapeutics market. On the basis of therapeutic application, oncology dominates the next-generation antibody therapeutics market. The North America next-generation antibody therapeutics market is anticipated to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. One of the latest trends in the next-generation antibody therapeutics market is the increasing use of ADC technology. Various biotechnology and biopharmaceutical companies are actively involved in development and manufacture of next-generation antibodies. Some of the major players in the market are F. Hoffmann-La Roche Ltd., Dyax Corp., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen, Inc., Biogen, Bayer AG, and Xencor, Inc. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Major Next-generation Antibody Therapeutics Pipeline Drugs Chapter 6 Global Market Size and Forecast Chapter 7 Market Size and Forecast by Therapeutic Area Chapter 8 Market Size and Forecast by Technology Chapter 9 Market Size and Forecast by Geography Chapter 10 Competitive Scenario Chapter 11 Company Profiles - Amgen, Inc. - AstraZeneca - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen, Inc. - Kyowa Hakko Kirin Co., Ltd. - Pfizer, Inc. - Seattle Genetics, Inc. - Takeda Pharmaceuticals Company Limited - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/zq...bal_market
SGEN: 42.81 (+0.46), PFE: 33.27 (-0.12), IMGN: 12.49 (-0.32), AMGN: 151.55 (+0.57), BMY: 64.15 (+0.43), XNCR: 12.97 (+0.09), DYAX: 34.42 (+0.03)
Immunogen Has Returned 11.6% Since SmarTrend Recommendation (IMGN)
Comtex SmarTrend(R) - Wed Nov 04, 12:20PM CST
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 11.59% as of today's recent price of $12.63.
IMGN: 12.49 (-0.32)
ImmunoGen, Inc. Pushes Its Pipeline Forward
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 31, 7:00AM CDT
ImmunoGen reported results from its first fiscal quarter on Tuesday, but there wasn't much to talk about on the financial side. Sales of Kadcyla, the first drug the biotech helped develop, aren't particularly material after ImmunoGen sold the...
JNJ: 99.88 (-0.39), IMGN: 12.49 (-0.32)
Downtrend Call Working As Immunogen Stock Falls 22.2% (IMGN)
Comtex SmarTrend(R) - Wed Oct 28, 10:50AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 22.19% as of today's recent price of $11.12.
IMGN: 12.49 (-0.32)
Shares of IMGN Down 25.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 28, 10:25AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 25.03% as of today's recent price of $10.71.
IMGN: 12.49 (-0.32)
ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 8:40AM CDT
ImmunoGen (IMGN) reported a loss of 39 cents per share in the first quarter fiscal 2016 with total revenues of $14.9 million.
AZN: 31.29 (+0.44), IMGN: 12.49 (-0.32), AMAG: 29.47 (+0.56)
ImmunoGen's (IMGN) Q1FY16 Loss Wider-than-Expected
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 7:34AM CDT
ImmunoGen reported a wider-than-expected loss in the first quarter of fiscal 2016.
IMGN: 12.49 (-0.32)
ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Business Wire - Tue Oct 27, 5:30AM CDT
--Level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine, ImmunoGen's novel folate receptor a (FRa)-targeting antibody-drug conjugate (ADC); data to be reported at AACR-NCI-EORTC in November.
IMGN: 12.49 (-0.32)
What Awaits ImmunoGen (IMGN) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Oct 26, 3:01PM CDT
ImmunoGen (IMGN) to report first quarter fiscal 2016 earnings results on Oct 27 before the market opens.
AQXP: 12.85 (+0.14), IMGN: 12.49 (-0.32), BMY: 64.15 (+0.43)
BUYINS.NET: IMGN SqueezeTrigger Price is $11.24. There is $120,266,048 That Short Sellers Still Need To Cover.
M2 - Mon Oct 26, 11:35AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Immunogen Inc (NASDAQ:IMGN) in real time and just received an alert that IMGN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 10586800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $11.24. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
IMGN: 12.49 (-0.32)
Immunogen Down 25.1% Since SmarTrend Downtrend Call (IMGN)
Comtex SmarTrend(R) - Wed Oct 21, 9:18AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 25.10% as of today's recent price of $10.70.
IMGN: 12.49 (-0.32)
Ergomed Ups the Ante for CEL-SCI
ACCESSWIRE - Wed Oct 21, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Cancer immunotherapy company CEL-SCI Corp. (NYSE MKT: CVM) is thriving. Ergomed, a multinational Contract Research Organization (CRO) with a pristine reputation and the confidence in CEL-SCI's lead drug Multikine to make a huge upfront $10 million investment, recently raised the ante 20% - to $12 million. The deal was done under the same terms first put in place that calls for only a single-digit royalty on potential sales. This clearly shows Ergomed's confidence not only in the likelihood of Multikine being approved, but also in the large revenue potential of the cancer immunotherapy drug.
MNK: 56.94 (+3.53), INO: 7.08 (+0.03), SNTA: 0.43 (-0.01), PCYC: 261.25 (+1.70), ADRO: 29.09 (+0.63), CVM: 0.49 (-0.01), IMGN: 12.49 (-0.32), CLLS: 35.83 (-0.53), AEZS: 0.05 (unch), JUNO: 50.00 (+0.11), BMY: 64.15 (+0.43)
Immunogen Shares Down 28.0% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Tue Oct 13, 4:54PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 28.04% as of today's recent price of $10.28.
IMGN: 12.49 (-0.32)
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results
Business Wire - Tue Oct 13, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Tuesday, October 27, 2015, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2015. Management also will provide an update on the Company.
IMGN: 12.49 (-0.32)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.64 (-0.09), BIIB: 284.84 (-6.49), NWBO: 4.54 (+0.02), CVM: 0.49 (-0.01), CLDX: 14.23 (+0.22), MACK: 9.12 (+0.29), INO: 7.08 (+0.03), NLNK: 35.90 (+0.94), JUNO: 50.00 (+0.11), GALE: 1.50 (+0.02), IMMU: 3.13 (+0.02), ADXS: 13.36 (+0.47), ADRO: 29.09 (+0.63), IMGN: 12.49 (-0.32), AMGN: 151.55 (+0.57), SPPI: 5.24 (+0.17), LLY: 79.55 (-0.31), BMY: 64.15 (+0.43), GSK: 39.87 (-0.18), SRNE: 8.79 (+0.21), ONTY: 3.46 (+0.19), IMUC: 0.46 (-0.01), PGNX: 6.71 (-0.03), ARGS: 4.27 (-0.04), GBIM: 2.21 (-0.22), BLCM: 20.88 (+0.02), SGEN: 42.81 (+0.46), KITE: 81.33 (+1.52), MRK: 53.03 (unch)
Immunogen Has Returned 24.8% Since SmarTrend Recommendation (IMGN)
Comtex SmarTrend(R) - Tue Oct 06, 11:29AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 24.82% as of today's recent price of $10.74.
IMGN: 12.49 (-0.32)
Shares of IMGN Down 30.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 29, 9:53AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 30.07% as of today's recent price of $9.99.
IMGN: 12.49 (-0.32)
